Drugs / KIg10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03961009 | Apr 2019 → Dec 2020 | immunodeficiency disease | Kedrion S.p.A. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIg10 | “This study was conducted to evaluate the safety and efficacy of a newly formulated IVIg, Kedrion IVIg 10% (KIg10).” PMID 42105146 ↗ May 2026 |
| Known as | Kedrion Immunoglobulin 10% | “The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).” NCT03961009 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin G (IVIg) therapy” PMID 42105146 ↗ May 2026 |
| Route | Intravenous | “Participants received intravenous infusion of Kedrion IVIG 10%” NCT03961009 ↗ |